Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab + R-MA vs R-MA in Treatment-naive PCNSL
NCT07764601Not yet recruiting
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of penpulimab in primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL) (2 arms). Primary endpoint: Progression-Free Survival at 2 years. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
penpulimab
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07764601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07764601.